Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly (Q40505030)

21 September 2017

Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly (English)

1 reference

21 September 2017

0 references

0 references

2

0 references

Joseph Kamgno

1

object named as

Joseph Kamgno

1 reference

21 September 2017

6

Michel Boussinesq

1 reference

21 September 2017

Nathalie Gardon-Wendel

3

1 reference

PubMed ID

15186939

21 September 2017

Demanga-Ngangue

4

1 reference

PubMed ID

15186939

21 September 2017

Brian O L Duke

5

1 reference

21 September 2017

1 August 2004

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

21 September 2017

1 reference

21 September 2017

98

1 reference

21 September 2017

496-504

1 reference

21 September 2017

8

1 reference

The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients.

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Relationships between the prevalence and intensity of Loa loa infection in the Central province of Cameroon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Neutrophil accumulation around Onchocerca worms and chemotaxis of neutrophils are dependent on Wolbachia endobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Eotaxin and RANTES expression by the dermal endothelium is associated with eosinophil infiltration after ivermectin treatment of onchocerciasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Country-wide rapid epidemiological mapping of onchocerciasis (REMO) in Cameroon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Neutrophil activation in ivermectin-treated onchocerciasis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2003.10.018

10.1016/J.TRSTMH.2003.10.018

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

15186939